open access

Vol 16, No 5 (2012)
REVIEV
Published online: 2013-03-21
Get Citation

Candesartan in the treatment of arterial hypertension and its cardiovascular complications

Ludwina Szczepaniak-Chicheł, Andrzej Tykarski
Nadciśnienie tętnicze 2012;16(5):311-320.

open access

Vol 16, No 5 (2012)
REVIEV
Published online: 2013-03-21

Abstract

Candesartan, a selective angiotensin II AT1 receptor
blocker is used in arterial hypertension in monotherapy or
in combined treatment. On the contrary to ACE inhibitors
candesartan does not influence the bradykinine levels
hence incidence of dry cough and angioedema is much
lower. Majority of the hypotensive effect of the drug is
being observed after the first two weeks of chronic therapy
and full influence after 4–6 weeks of regular pharmacotherapy
and does not diminish in longitudinal annual observation.
The publication aims at brief description, in the
light of data from available large clinical trials, of the
candesartan’s hypotensive effectiveness in comparison with
other hypotensive agents or in combination with them, its
influence on left ventricle hypertrophy, heart failure, cerebrovascular
risk and new-onset diabetes incidence.

Abstract

Candesartan, a selective angiotensin II AT1 receptor
blocker is used in arterial hypertension in monotherapy or
in combined treatment. On the contrary to ACE inhibitors
candesartan does not influence the bradykinine levels
hence incidence of dry cough and angioedema is much
lower. Majority of the hypotensive effect of the drug is
being observed after the first two weeks of chronic therapy
and full influence after 4–6 weeks of regular pharmacotherapy
and does not diminish in longitudinal annual observation.
The publication aims at brief description, in the
light of data from available large clinical trials, of the
candesartan’s hypotensive effectiveness in comparison with
other hypotensive agents or in combination with them, its
influence on left ventricle hypertrophy, heart failure, cerebrovascular
risk and new-onset diabetes incidence.
Get Citation

Keywords

candesartan, arterial hypertension, hypotensive effectiveness, cardiovascular complications

About this article
Title

Candesartan in the treatment of arterial hypertension and its cardiovascular complications

Journal

Arterial Hypertension

Issue

Vol 16, No 5 (2012)

Pages

311-320

Published online

2013-03-21

Bibliographic record

Nadciśnienie tętnicze 2012;16(5):311-320.

Keywords

candesartan
arterial hypertension
hypotensive effectiveness
cardiovascular complications

Authors

Ludwina Szczepaniak-Chicheł
Andrzej Tykarski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl